Welcome to our dedicated page for Clearmind Medicine SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clearmind Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clearmind Medicine's regulatory disclosures and financial reporting.
Clearmind Medicine Inc. (NASDAQ: CMND) filed a Form 6-K for June 2025. The filing mainly furnishes a press release dated 27 June 2025 entitled “Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market.”
Key points disclosed:
- The company is expanding its global clinical trial program aimed at Alcohol Use Disorder (AUD), a market the company characterises as multibillion-dollar.
- The first four paragraphs of the press release are automatically incorporated by reference into Clearmind’s effective shelf registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and its equity incentive Form S-8 (File No. 333-283695).
- No financial metrics, study data, or timelines are provided in the filing itself.
- The document is informational only; it does not request shareholder action nor announce financing.
The 6-K was signed by CEO Adi Zuloff-Shani on 27 June 2025.
Clearmind Medicine Inc. (CMND) has filed a Form 6-K for June 2025.
The filing mainly furnishes a press release dated 23 June 2025 entitled “Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder.” No financial statements, earnings data, or transactional details accompany the report. The company simply notifies investors that the first two paragraphs of the press release are incorporated by reference into several existing U.S. registration statements on Forms F-3 (File Nos. 333-275991, 333-270859, 333-273293) and S-8 (File No. 333-283695).
The filing is signed by CEO Adi Zuloff-Shani on 23 June 2025. Aside from the clinical-site expansion disclosure, there are no other material events, financial metrics, or risk factors discussed.
On June 18, 2025, the U.S. Securities and Exchange Commission declared effective Clearmind Medicine Inc.’s post-effective amendment to its registration statement (Submission Type: POS AM, File No. 333-276913, Accession No. 0001213900-25-053898). This Notice of Effectiveness (Form EFFECT) confirms that the company’s shelf registration is now operative.
The filing contains no financial statements, earnings data, or details of securities to be immediately issued. It is a routine administrative step that gives Clearmind Medicine the legal authority to offer and sell the securities covered by the registration statement at a future date; it does not, by itself, change the company’s operations or financial position.